Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Adults With Binge Eating Disorder
NCT06878976Phase 3Enrolling by invitation
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Solriamfetol with Placebo (2 arms). Primary endpoint: Time from randomization to relapse of binge eating in the RW segment at 24 weeks. Started Feb 2025; status: enrolling by invitation.
02
Drugs
solriamfetol
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT06878976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878976.